| __timestamp | BioMarin Pharmaceutical Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 35942000 |
| Thursday, January 1, 2015 | 402271000 | 40028000 |
| Friday, January 1, 2016 | 476593000 | 45853000 |
| Sunday, January 1, 2017 | 554336000 | 53816000 |
| Monday, January 1, 2018 | 604353000 | 60804000 |
| Tuesday, January 1, 2019 | 680924000 | 77252000 |
| Wednesday, January 1, 2020 | 737669000 | 45736000 |
| Friday, January 1, 2021 | 759375000 | 50323000 |
| Saturday, January 1, 2022 | 854009000 | 143526000 |
| Sunday, January 1, 2023 | 937300000 | 149182000 |
| Monday, January 1, 2024 | 1009025000 | 154335000 |
Data in motion
In the competitive world of biotechnology, effective cost management is crucial for sustained growth. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc. from 2014 to 2023. Over this period, BioMarin's SG&A expenses surged by over 200%, reflecting its aggressive expansion strategy. In contrast, Halozyme's expenses grew by approximately 315%, indicating a robust scaling of operations.
BioMarin's SG&A expenses increased steadily, peaking in 2023. This growth underscores the company's commitment to expanding its market presence and enhancing its operational capabilities.
Halozyme's expenses, while lower in absolute terms, showed a remarkable upward trend, particularly between 2022 and 2023, where they jumped by over 4%. This suggests a strategic push towards broader market penetration.
Understanding these trends offers valuable insights into the financial strategies of these biotech leaders.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Halozyme Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Insmed Incorporated vs BioMarin Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Ascendis Pharma A/S
Who Generates Higher Gross Profit? BioMarin Pharmaceutical Inc. or Halozyme Therapeutics, Inc.
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Halozyme Therapeutics, Inc. or Opthea Limited: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Axsome Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Alpine Immune Sciences, Inc.
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs PTC Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Galapagos NV